D. A. S. Compston

Alemtuzumab versus interferon beta 1a as first-line treatment for patients with relapsing-remitting multiple sclerosis: a randomised controlled phase 3 trial

Jeffrey Cohen, Alasdair Coles, Douglas L. Arnold et al. · The Lancet · 2012 · 1.2K citations

Rheumatology, Relapsing-remitting Multiple Sclerosis, Immunology +8

Alemtuzumab for patients with relapsing multiple sclerosis after disease-modifying therapy: a randomised controlled phase 3 trial

Alasdair Coles, Cary Twyman, Douglas L. Arnold et al. · The Lancet · 2012 · 1.2K citations · Full text

Immunology, Clinical Trials, Neurological Progress +4

Multiple Sclerosis Severity Score

Richard Roxburgh, Shaun R. Seaman, Thomas Masterman et al. · Neurology · 2005 · 945 citations

A genetic study of von Recklinghausen neurofibromatosis in south east Wales. I. Prevalence, fitness, mutation rate, and effect of parental transmission on severity.

Susan Huson, D. A. S. Compston, Peggy Clark et al. · Journal of Medical Genetics · 1989 · 542 citations · Full text

Mendelian Disorder, Genetic Disorder, Medicine +15

The window of therapeutic opportunity in multiple sclerosis

Alasdair Coles, Amanda Cox, Emmanuelle Le Page et al. · Journal of Neurology · 2005 · 501 citations

Neurological Disorder, Medicine, Rehabilitation +5